Rigor Reviewed

Rigor-Reviewed Manuscript

Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial.

Name: Αlpha¹ Rigor Record — Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial.
Item: Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial.
Rating: 100
Author: Αlpha¹

Cardoso F, O'Shaughnessy J, Liu Z, McArthur H, Schmid P, Cortes J, Harbeck N, Telli ML, Cescon DW, Fasching PA, Shao Z, Loirat D, Park YH, Fernandez MG, Rubovszky G, Spring L, Im SA, Hui R, Takano T, André F, Yasojima H, Ding Y, Jia L, Karantza V, Tryfonidis K, Bardia A

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.5★ (Adequate), 0 critical, 0 high issues for “Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced2 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a rigorously designed and reported phase 3 randomized controlled trial. The methodology is strong across all dimensions, with clear randomization, blinding, power analysis, and statistical methods. Minor reporting gaps include lack of explicit CONSORT mention and regulatory compliance statement, but these do not undermine the overall integrity.

Both reviewers classified the study as interventional, and no divergence was noted. The evaluation covered all eight dimensions; non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification covered only 2 tests, so the statistical analysis is not fully independently verified.

6 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites prior studies (I-SPY2, KEYNOTE-522) and a meta-analysis correlating pCR with EFS/OS, providing a strong rationale for the trial. It also acknowledges the heterogeneity of ER+ disease and the need for better treatments in high-risk subgroups. Limitations of prior research are addressed by designing a phase 3 trial with dual primary endpoints.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study clearly establishes its scientific premise with prior work, a logical rationale, and addresses limitations of prior research.

Evidence

paraphrase[Introduction, paragraph 1]

“For these patients, reported pathological complete response (pCR) rates range from 0% to 18% and event-free survival (EFS) rates are similar to those of patients with triple-negative breast cancer (TNBC).”

paraphrase[Introduction, paragraph 2]

“Building on these results, KEYNOTE-756 was designed as a randomized, double-blind, phase 3 study to evaluate the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy versus neoadjuvant placebo plus chemotherapy followed by adjuvant placebo plus endocrine therapy.”

paraphrase[Introduction, paragraph 2]

“The study builds on phase 2 I-SPY2 results and phase 3 KEYNOTE-522 results, addressing the need for a definitive phase 3 trial in ER+/HER2- disease.”

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with prior work cited, a logical rationale, and addresses limitations of prior research.

Evidence

paraphrase[Introduction, paragraph 1]

paraphrase[Introduction, paragraph 2]

“Combination therapy with immune checkpoint inhibitors plus chemotherapy induces changes to the tumor microenvironment that may enhance endogenous anticancer immunity, reduce tumor volume and increase response rate compared with chemotherapy alone.”

paraphrase[Introduction, paragraph 2]

Randomization method (central interactive voice-response system) and unit (patient) are described. Blinding is double-blind with placebo control. Power analysis is provided (>99% power for pCR, 84% for EFS). Inclusion/exclusion criteria are detailed. Outlier handling is addressed via ITT and as-treated populations. Controls are the placebo arm. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and inclusion/exclusion criteria.

Evidence

direct quote[Methods, Trial design and treatment]

“Patients were randomly assigned (in a 1:1 ratio) to the pembrolizumab–chemotherapy arm or the placebo–chemotherapy arm using a central interactive voice-response system with an integrated web-response system.”